Overall , individuals allocated to alemtuzumab-based treatment had a 58 % proportional reduction in biopsy-proven acute rejection compared with those allocated to basiliximab-based treatment ( 31 [ 7 % ] patients in the alemtuzumab group vs 68 [ 16 % ] patients in the basiliximab group ; hazard ratio ( HR ) 042 , 95 % CI 028-064 ; log-rank p < 00001 ) .